Tallac Therapeutics Announces First Patient Dosed with TAC-001, a First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugate, in a Phase 1/2 Study for Patients with Advanced Solid Tumors
— TAC-001 is the First Candidate from Tallac’s Novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) Platform to Enter the Clinic BURLINGAME, Calif.–(BUSINESS WIRE)–Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced that the first patient has been dosed with TAC-001 in a Phase … [Read more…]
